Educated Patient® Multiple Myeloma Summit

Watch Dr. Sham Mailankody, from Memorial Sloan Kettering Cancer Center, discuss CAR and BiTE therapy, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Saad Z. Usmani, Dr. Ben Marcus and Stan Wagner discuss their participation in the Moving Mountains for Multiple Myeloma program, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Kristie L. Kahl, Donna and Jack McNutt, Dr. Noopur Raje, and Grace Allison, discuss treating myeloma long term, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Saad Z. Usmani, Dr. Krina K. Patel, Dr. Noa Biran, and Jenny Ahlstrom, answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

Treating multiple myeloma to minimize the amount of residual disease in the body is an ultimate goal, which can be achieved through initial therapy and maintenance therapy.

Patients with myeloma should not be afraid to seek out second opinions or speak up about side effects that they are experiencing.

View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.

All patients with multiple myeloma have had MGUS, so what is it?

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center discusses how she changed her perspective on finding a cure for myeloma and what her goals are when it comes to treating her patients.

CURE® is looking back at the Educated Patient® Multiple Myeloma Summit, a half-day virtual event to educate, inform and connect patients with multiple myeloma to a variety of experts in the field.

In an interview, Dr. Andrew Yee of Massachusetts General Hospital discusses how a multiple myeloma diagnosis affects a patient’s life and how hopeful he is about helping them lead normal lives.

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

The biggest fear for many patients, according to an expert from The University of Texas MD Anderson Cancer Center, is when they hear that myeloma, for most patients, is not curable. However, she notes that every few years patient survival is increasing.

An expert discusses therapies that are changing the treatment landscape and the research to make this disease more livable.

There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to an expert.

Although a multiple myeloma diagnosis can be overwhelming for patients, an expert from the Massachusetts General Hospital Cancer Center notes how the disease is very treatable, and that patients can go on to lead full lives.

An expert discusses the treatment options that patients with early relapse myeloma have to treat their recurrent disease, which often follows a cyclical pattern.

View the full CURE Educated Patient Multiple Myeloma Summit on demand.

In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.

Advancements in the diagnosis and staging of multiple myeloma continue to shape treatment decisions and improve outcomes.

In an interview with CURE®, Dr. Giada Bianchi provides patients an overview of myeloma, including symptoms and risk factors of the disease people should look out for.

The complexity of multiple myeloma can make it difficult to treat, but with complexity comes more avenues for researchers to explore what treatments work best. Recently, CURE® spoke with an expert from Dana-Farber Cancer Institute on what patients can expect to see from the clinical setting.

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.